Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma

(2018) Priscilla Brito da Silva et al.   HEMATOLOGICAL ONCOLOGY

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma

(2018) Jun Ho Yi et al.   CYTOKINE

Primary CNS Lymphoma

(2017) Christian Grommes et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

(2017) D Rossille et al.   LEUKEMIA

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

(2017) Yusuke Okuma et al.   LUNG CANCER

The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1

(2017) Yasuo Sugita et al.   NEUROPATHOLOGY

The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis

(2017) Y. Ding et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

(2017) Hyunsoo Cho et al.   Oncotarget

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival

(2016) Marion Four et al.   HEMATOLOGICAL ONCOLOGY

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

(2016) Jung Yong Hong et al.   HEMATOLOGICAL ONCOLOGY

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

(2016) Andreas H Scheel et al.   MODERN PATHOLOGY

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

(2016) Sophie Langner-Lemercier et al.   NEURO-ONCOLOGY

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

(2016) Hyerim Ha et al.   Oncotarget

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

Targetable genetic features of primary testicular and primary central nervous system lymphomas

(2015) B. Chapuy et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients

(2015) Seok Jin Kim et al.   Journal of Hematology & Oncology

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

(2015) Khê Hoang-Xuan et al.   LANCET ONCOLOGY

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

(2015) Therese Phillips et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)

(2013) Anna Sophie Berghoff et al.   CLINICAL NEUROPATHOLOGY

Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation

(2013) Moon Ki Choi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Diagnosis and treatment of primary CNS lymphoma

(2013) Agnieszka Korfel et al.   Nature Reviews Neurology

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

(2013) E. J. Lipson et al.   Cancer Immunology Research

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Primary Central Nervous System Lymphoma

(2010) Elizabeth R. Gerstner et al.   ARCHIVES OF NEUROLOGY

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

(2010) Eckhard Thiel et al.   LANCET ONCOLOGY

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

(2009) Andrés JM Ferreri et al.   LANCET

Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

(2008) Carole Soussain et al.   JOURNAL OF CLINICAL ONCOLOGY